%PDF-1.6
%
65 0 obj
<>stream
hP0Pw/+Q0L)64
T$
endstream
endobj
66 0 obj
<>stream
h2S0P0W0P+-q
b".vv 7
endstream
endobj
67 0 obj
<>stream
hd
@_e`exD 7n8F ϋ3'ב3=6G6ar{lhl֖
!\tʛ zZ36t@JPfei
%f5Ӯn)zY"NN+YAď_ RC9
endstream
endobj
68 0 obj
<>stream
hޜJ1W(
Ъł^ts v`dzۛZ*^B2AРUis\֞㝋ckXr9n3-;nc!9尕a{ʔne!ůEFHB PWSLڋiã(GfM).}SiV~W[3K.,W3|2> Z4
endstream
endobj
2 0 obj
<>stream
PScript5.dll Version 5.2.2
2019-11-13T10:59:10-05:00
2019-11-12T12:05:46-05:00
2019-11-13T10:59:10-05:00
application/pdf
Lenalidomide-Related Diarrhea Correlates with Disease Control in Newly Diagnosed
Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN
In this activity, Dr. Beth Faiman covers how to manage lenalidomide-related diarrhea in newly diagnosed patients with multiple myeloma.
lenalidomide-related diarrhea
lenalidomide
diarrhea
disease control
multiple myeloma
histopathologic findings of lymphocytic infiltrate
colonic biopsies
immune effect
hematologic stem cell transplant
chemotherapies
dexamethasone
IgA
antibody-based immune protection
hematic stem cell transplantation
Acrobat Distiller 11.0 (Windows)
lenalidomide-related diarrhea, lenalidomide, diarrhea, disease control, multiple myeloma, histopathologic findings of lymphocytic infiltrate, colonic biopsies, immune effect, hematologic stem cell transplant, chemotherapies, dexamethasone, IgA, antibody-based immune protection, hematic stem cell transplantation
uuid:efdad2ca-7249-4862-a2a4-b56dbc723d0a
uuid:7e3eab16-53b8-4002-8255-e19197331f67
endstream
endobj
11 0 obj
<>
endobj
43 0 obj
<>
endobj
49 0 obj
<>stream
HWko_1@l)n]Ԏo,zZ\LPȕy,EZQ
,>vggΜ93]nonN֙JᏫU?SpJRՊm^%:+].`t˳vtZ9zڌ<'D`,n?V>ܟZtW\]oaf.3?z9ko>o=cK8xGx)TM_-m~#翍 B"ǎ"hTCy4=s=:.GWzs8F6GӣrD3-Fϸ%.MKg7DnJx=e |yěȂ ۛ/HO ܌yhIA\Ō#%;!bzZ49FG`ͣY+|7ّTnt*V_=+]tQoTte: QgbF`^÷Y(
˅(F!;f! _gī͇YJ<2DC\M{I2quӋ5Uo[zoaP\5wOX : x|?G)"F:Tɹ>gy}GG+d%
KF۴]\-GJ